You are here
News & Events
Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Sep 17, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 7,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf registration statement on file with the Securities and Exchange Commission. Vertex intends to grant the underwriters an option to purchase up to an additional 1,050,000 shares of its common stock.
Goldman, Sachs & Co. is acting as the sole book-runner for the offering.
This press release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offer of shares of common stock will be made only by means of a prospectus, including a prospectus supplement, forming a part of the automatically effective shelf registration statement. A copy of the prospectus for the offering can be obtained from Goldman Sachs & Co.'s prospectus department, at 85 Broad Street, New York, New York 10004, Fax: 212-902-9316 or Email at email@example.com.
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and cystic fibrosis. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.
Lexiva is a registered trademark of the GlaxoSmithKline group of companies.
Vertex's press releases are available at www.vrtx.com.
SOURCE: Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated Michael Partridge, Senior Director, Strategic Communications 617-444-6108 or Lora Pike, Manager, Investor Relations 617-444-6755
Copyright Business Wire 2008
News Provided by COMTEX